NewsRoom Articles - Page 101 of 154 - PsychedelicNewsWire (PNW)

ThursdayApr 15, 2021 12:00 pm

California Senate Committee Approves Psychedelic Decriminalization Measure

Earlier this month, a measure to decriminalize psychedelics in the state of California was advanced to the Senate Public Safety Committee. The committee also passed a separate bill that would enable communities in the state to temporarily open safe consumption sites for illegal drugs. The legislation, sponsored by Sen. Scott Wiener, was approved by the Senate Public Safety Committee. If the bill is enacted into law, it would remove criminal penalties imposed on the distribution or possession of an extensive range of psychedelics, including MDMA, LSD, ibogaine, DMT and psilocybin mushrooms, for individuals aged 21 and above. The initiative would…

WednesdayApr 14, 2021 12:00 pm

Women in the Psychedelic Field and the Barriers That Held Them Back

Women have contributed greatly to the psychedelics industry, accomplishing incredible research and work in the field, despite being maligned in serious ways for just being involved. Given that International Women’s Month has just ended, the timing seems ideal to shine a spotlight on women pioneers of psychedelics, along with a focus on what exactly held them back. Women have had to jump through hurdles that did not exist for their male counterparts as well as bypass barriers in various industries and fields, including the field of psychedelic research. Knowledge of history or sometimes just personal experience has shown that the…

TuesdayApr 13, 2021 2:15 pm

Another City in Massachusetts Approves Measure to Decriminalize Psychedelics

A third city in Massachusetts, Northampton, has passed an initiative to make the distribution, use and possession of various psychedelics, such as ayahuasca and psilocybin, one of the lowest priorities of law enforcement in the area. Prior to this, the cities of Cambridge and Somerville had also approved measures to effectively decriminalize psychedelics. The Northampton City Council approved the measure, which also stipulates that no police or government funds should be utilized in enforcing laws that criminalize individuals for the possession or use of entheogenic fungi and plants. The city council voted on the resolution this past week, with a…

MondayApr 12, 2021 3:00 pm

New UCSF Research Program to Focus on Psychedelics Research and Treatments’ Advancement

The formation of the University of California Neuroscape Psychedelics Division will help advance psychedelic research on brain health through $6.4 million in private financing. The new division at UCSF will employ a translational research approach that will integrate psychedelic treatment with groundbreaking neuroscience technology. The first project to be undertaken will be a MAPS phase 3 trial for the evaluation of MDMA, commonly known as ecstasy, as a new PTSD treatment. Neuroscape executive director Adam Gazzaley stated that the financiers of the center are helping facilitate a great leap forward in producing evidence of the clinical safety and effectiveness of…

MondayApr 12, 2021 2:10 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Signs Letter of Intent to Co-Develop Psychedelic Mushroom-Based Psilocybin Formulations

PULL signs Letter of Intent with Psyence Group to co-develop extraction techniques for production of psilocybin drug formulations Psyence is one of world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility PULL operates best-in-class processing infrastructure under Standard Processing License by Health Canada Near term milestones include Canada-based human clinical trials Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, recently signed a Letter of Intent with the Psyence Group to develop premium extraction techniques for the production of…

MondayApr 12, 2021 1:01 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Files First Order for Rapid COVID Test Kits Amid European Regulatory Approval

Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April XPhyto has just completed a rebranding effort that includes…

FridayApr 09, 2021 2:44 pm

Integration Proves Its Importance When Treating Mental Conditions Using Psychedelics

For a big chunk of his adult life, Nick Watchorn suffered from serious PTSD, before seeking psychedelic treatments, which helped him manage his condition. Watchorn revealed that the psychoactive sessions he attended and the work that he did on himself afterwards, through a process he refers to as integration, saved his life. He states that before he received the therapeutic treatments (MDMA-assisted therapy), he thought he was too far gone. Watchorn, now 54, had been plagued for more than two decades by the memories of a mass shooting that he’d experienced as a young police officer. The shooting, which occurred…

ThursdayApr 08, 2021 2:25 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commercialization Team Set to Launch Rapid POC COVID Test Solution

Bioscience technology accelerator XPhyto Therapeutics Corp. is working with development partner 3a-diagnostics GmbH to roll out its pandemic-related virus diagnostic tool for the European market planned in April The test solution, dubbed “Covid-ID Lab,” received European regulatory approval last month XPhyto’s product is designed to be portable and rapid in its response time to help decrease testing operation costs and increase convenience of use News reports about the COVID-19 pandemic reflect a growing optimism that vaccine, mask and distancing protocols may be helping to drive down infection rates, although the reports note the virus continues to have a deadly effect…

ThursdayApr 08, 2021 11:15 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) at Front of Line for Cutting-Edge Vitalis Extraction Technology

Annual growth of 17% is forecast for cannabis extraction market to reach $28.5 billion by 2027 Pure Extracts Technologies is already operating leading extraction systems from Vitalis and will soon become one of the first companies to have Vitalis’ new Cosolvent Injection System (“CIS”) The CIS delivers dramatically faster throughput capacities, even higher-quality cannabis extracts, optimal ethanol cosolvent flow rates and low ethanol usage Analysts are aligned on the future of the cannabis extraction market, with expectations for years of double-digit compound annual growth rates. The market experts at Grand View Research see 16.6% CAGR for the market to reach…

ThursdayApr 08, 2021 10:00 am

Three Studies Investigate the Role of Psychedelics in Treating OCD

Recent psychedelic research has led to significant breakthroughs in the field. The substances have been found to be useful in treating various mental health conditions such as depression as well as addiction. Additionally, new research has found that psilocybin, which is the active ingredient in magic mushrooms, is useful in treating obsessive-compulsive disorder (“OCD”). There are three studies looking into the use of psilocybin to decrease the symptoms of obsessive-compulsive disorder. While each study is using different treatment techniques, the evidence they’ve uncovered may be crucial in helping researchers understand the therapeutic mechanism behind psychedelic drugs. Generally, OCD is characterized…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000